ArticleDiscover oncology2025
Lon peptidase 1 promotes proliferation and metastasis in breast cancer via interleukin 6 signaling.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTriple-negative breast cancer (TNBC) remains a therapeutic challenge due to its aggressive behavior and lack of targeted therapies. Mitochondrial protease Lon Peptidase 1 (LONP1) has been associated with cancer progression; however, its clinical relevance and mechanistic role in triple-negative breast cancer (TNBC) remain unclear. This study investigates LONP1 as a potential prognostic biomarker and therapeutic target in breast cancer, with emphasis on TNBC.
methodsWe performed multi-omics analyses by integrating RNA-seq data from TCGA, GEO, and METABRIC cohorts. Functional studies were conducted using five breast cancer cell lines (BT-474, BT-549, MCF-7, MDA-MB-231 [TNBC], T-47D) with LONP1 knockdown or overexpression. Cell proliferation, migration, and invasion were assessed in vitro. In vivo tumorigenicity was evaluated in BALB/c nude mice. Mechanistic investigations included transcriptomic profiling and validation of IL-6 signaling using qPCR and Western blot.
resultsLONP1 was significantly overexpressed in TNBC versus non-TNBC tissues, correlating with advanced stage and poor survival. Functionally, LONP1 overexpression increased proliferation, migration, and invasion in models, while in vivo tumors exhibited accelerated growth. Transcriptomics revealed IL-6/JAK-STAT3 pathway activation, confirmed by upregulated IL-6 expression in LONP1-high cells.
conclusionLONP1 promotes TNBC progression through IL-6-mediated oncogenic signaling, indicating its potential as both a prognostic biomarker and a therapeutic target in aggressive breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.